Treatment strategies for space motion sickness were compared using the results of postflight oral debriefings. Standardized questionnaires were administered to all crewmembers immediately following Space Shuttle flights by NASA flight surgeons. Cases of space motion sickness were graded as mild, moderate, or severe based on published criteria, and medication effectiveness was judged based on subjective reports of symptom relief. Since October 1989, medication effectiveness is reported inflight through private medical conferences with the crew. A symptom matrix was analyzed for nineteen crewmembers treated with an oral combination of scopolomine and dextroamphetamine (scopdex) and fifteen crewmembers treated with promethazine delivered by intramuscular or suppository routes. Scopdex has been given preflight as prophylaxis for space motion sickness but analysis showed delayed symptom presentation in nine crewmembers or failed to prevent symptoms in seven.
Comparison of treatment strategies for space motion sickness
01.10.1991
Aufsatz (Konferenz)
Keine Angabe
Englisch
Comparison of treatment strategies for Space Motion Sickness
Online Contents | 1993
|NTRS | 1979
|Managing Space Motion Sickness
IOS Press | 1998
Space Motion Sickness Status Report
SAE Technical Papers | 1986
|